Newsroom
Sorted by: Latest
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
NUBURU Advances $2.2 Million Blue-Laser Rover Opportunity, Supporting Progress Toward 2026 Revenue Targets for Its LaserTech Business Line
DENVER--(BUSINESS WIRE)--NUBURU, Inc. (NYSE American: BURU) (“NUBURU” or the “Company”), the next-generation dual-use Defense & Security integrated platform company focused on non-kinetic effects and directed-energy technologies, electronic warfare and defense mobility programs, software-orchestrated defense systems and advanced manufacturing, today provided an update on the commercial pipeline of its photonics and laser activities, centered on Lyocon S.r.l. (“Lyocon”) and supported by the...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - June 19.06.2026 QJUN.LN IE000HFBJ0U0 3,800,002.00 USD 85,855,968.28 22.594 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - September 19.06.2026 QSEP.LN IE000FQ808R5 400,002.00 USD 9,828,086.66 24.570 ...
-
Transcat Announces Appointment of Roy Simmons as Chief Strategy and Corporate Development Officer
ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat Announces Appointment of Roy Simmons as Chief Strategy and Corporate Development Officer...
-
Return Abuse Goes Mainstream as Nearly Half of Consumers Use AI in Return Claims, New Riskified Research Finds
NEW YORK--(BUSINESS WIRE)--Riskified research finds return abuse is becoming mainstream as nearly half of consumers use AI in return claims, reshaping ecommerce risk....
-
Silver Bow Mining Reports Initial Assay Results From Drill Program
BUTTE, Mont.--(BUSINESS WIRE)--Silver Bow Mining reports drill results from Rainbow Block confirming Critical Mineral enrichment and vein extensions beyond resource estimate....
-
Thermo Fisher Scientific Showcases New Capabilities Across Manufacturing, Clinical Development and AI-Enabled Research at BIO International 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase new capabilities, strategic investments and initiatives at BIO International 2026 that are helping pharma and biotech customers advance innovation, simplify complex workflows and bring therapies to patients faster. Spanning AI-enabled research, clinical development and advanced manufacturing, these investments reinforce Thermo Fisher’s role as a trusted strategic provider of integrated...